Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05329935 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Congenital Athymia Patient Registry

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 19, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. 3 versions Re-verified since Mar 13, 2024, no change to tracked fieldsv4-v6
  2. Start date changed from estimate of Apr 2022 to May 25, 2022v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).
Trial Details
NCT Number NCT05329935
Lead Sponsor Sumitomo Pharma Switzerland GmbH
Conditions
(from sponsor)		 Complete DiGeorge Anomaly, Complete DiGeorge Syndrome, Congenital Athymia
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov